These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

831 related items for PubMed ID: 17046021

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
    Li S, Salgar SK, Kurimoto Y, Yousem S, Pham SM.
    J Surg Res; 2008 May 15; 146(2):289-97. PubMed ID: 18314139
    [Abstract] [Full Text] [Related]

  • 3. [Adenovirus-mediated CTLA4 immunoglobulin based conditioning for non-myeloablative allogeneic hematopoietic cell transplantation to induce tolerance to hind limb allografts in rats].
    Pan H, Wang L, Zhang XD, Mai HX, Liu D, Liu Y, Guo SZ.
    Zhonghua Wai Ke Za Zhi; 2009 Jun 15; 47(12):937-40. PubMed ID: 19781252
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H, Zhao K, Wang L, Zheng Y, Zhang G, Mai H, Han Y, Yang L, Guo S.
    J Surg Res; 2010 May 15; 160(2):315-24. PubMed ID: 19524257
    [Abstract] [Full Text] [Related]

  • 8. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism.
    Li S, Thanikachalam M, Pang M, Carreno M, Aitouche A, Pham SM.
    Exp Hematol; 2001 Apr 15; 29(4):534-41. PubMed ID: 11301194
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
    Colson YL, Zadach K, Nalesnik M, Ildstad ST.
    Transplantation; 1995 Nov 15; 60(9):971-80. PubMed ID: 7491703
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Nov 15; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
    Okayama J, Ko S, Kanehiro H, Kanokogi H, Nakajima Y.
    J Surg Res; 2006 Jun 15; 133(2):61-8. PubMed ID: 16376943
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants.
    Chen B, Xu H, Corbin DR, Ildstad ST.
    Transplantation; 2012 Oct 15; 94(7):671-8. PubMed ID: 22948444
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
    Zhu ZX, Fan LY, Wang Q.
    Eur Surg Res; 2011 Oct 15; 46(3):109-17. PubMed ID: 21242693
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.